OPEN MARKET SALE AGREEMENT1Open Market Sale Agreement • August 5th, 2020 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances) • New York
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 5th, 2020 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances) • California
Employment Agreement (“Agreement”) made as of the 13th day of April, 2020 by and between Sangamo Therapeutics, Inc., a Delaware corporation (the “Company”), and Mark McClung (“Executive”) (collectively, the “Parties”).
EIGHTH AMENDMENT TO LEASELease • August 5th, 2020 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances)
THIS EIGHTH AMENDMENT TO LEASE (this “Eighth Amendment”) is entered into as of May 29, 2020 (the “Effective Date”), by and between POINT RICHMOND R&D ASSOCIATES II, LLC, a California limited liability company (“Landlord”), and SANGAMO THERAPEUTICS, INC., a Delaware corporation (formerly known as Sangamo Biosciences, Inc., a Delaware corporation) (“Tenant”), with reference to the following facts:
SEVENTH AMENDMENT TO LEASELease • August 5th, 2020 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances)
THIS SEVENTH AMENDMENT TO LEASE (this “Seventh Amendment”) is entered into as of May 20, 2020 (the “Effective Date”), by and between POINT RICHMOND R&D ASSOCIATES II, LLC, a California limited liability company (“Landlord”), and SANGAMO THERAPEUTICS, INC., a Delaware corporation (formerly known as Sangamo Biosciences, Inc., a Delaware corporation) (“Tenant”), with reference to the following facts:
